Peptides are frequently marketed online for weight loss, metabolism, recovery, and body composition, but the term “peptide therapy” includes very different substances with very different levels of evidence and regulatory status. Our approach is to separate established obesity treatments from investigational or unapproved peptide claims and to select therapy based on a comprehensive medical evaluation.
Some FDA-approved obesity medications are peptide-based or peptide-like therapies, including GLP-1 pathway medications. That does not mean every peptide promoted for fat loss has demonstrated safety and effectiveness for obesity. We distinguish FDA-approved weight-management medications from investigational compounds and substances with limited human evidence.
Patients commonly ask about GLP-1 medications, tirzepatide, retatrutide, tesamorelin, growth-hormone secretagogues and other peptides. Their roles are not equivalent. Semaglutide and tirzepatide have FDA-approved products for chronic weight management in appropriate patients. Retatrutide remains investigational. Tesamorelin has an FDA-approved indication for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, not general obesity.
Weight regulation can be influenced by sleep, medications, endocrine disorders, nutritional deficiencies, lifestyle, metabolic disease and other medical factors. When clinically appropriate, evaluation may include laboratory testing for thyroid, metabolic, hormonal, vitamin or nutritional abnormalities. The objective is to identify relevant contributors and create an individualized plan rather than simply prescribe an injection.
There is no single best treatment for every patient. Evidence and FDA status vary substantially among products. Treatment selection should consider diagnosis, BMI and comorbidities, medical history, contraindications, previous therapy, goals, tolerability and patient preference.
Some peptide-based medications have FDA-approved indications; many peptides promoted by wellness or research-product sellers do not. Each specific medication must be evaluated individually.
No. Evidence-based medical weight management generally integrates appropriate medication with nutrition, physical activity, sleep, behavior and ongoing medical follow-up.
Learn more about Peptide Therapy Los Angeles, GLP-1 weight loss, weight-loss injections, and nutrition and body composition.
Your initial visit establishes care and evaluates the medical and lifestyle factors relevant to your weight and metabolic health. Laboratory testing may be ordered when clinically appropriate. Follow-up physician visits are $250.
